FindMyKOL

Thomas Cosgriff, MD

Basic profile

East Jefferson General Hospital

ORCIDNone on fileNPIOn fileSign in to see identifiers
✓ Itemized record
RegionMetairie, LA · South CentralSpecialtyHematology / OncologyFocusOncology
Last active 2024FindMyKOL type: RegionalLatest publicationSee ScholarshipOnline presenceNot yet checkedPayments2021 onwardNIH fundingNot yet indexedWhy? →

Thomas Cosgriff is an Oncology physician affiliated with East Jefferson General Hospital. OpenAlex indexes 102 publications with 4,081 citations (h-index 28); ClinicalTrials.gov lists 1 registered study matched to this name.

Overview

Scholarship

indexed output and impact (OpenAlex)
102publications

Publications indexed by OpenAlex. Counts exclude supporting files.

4,081citations

Citations across these publications.

28h-index

H-index from these publications.

Clinical & industry

trials, payments and federal funding
1clinical trials

Investigator role on registered studies.

View trials ↓
38companies · 2021 onward

Companies reporting payments to CMS. Facts, not judgments.

View payments ↓

Clinical trials

Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.

Industry payments

38 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:

  • Merck & Co.
    Program year20251 paymentResearch
    $117
  • Pfizer
    Program year20244 paymentsResearch
    $9,529
  • PFIZER INC.
    Program year20248 payments
    $135
All 68 payment records: search, sort and filter.Explore →

Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward. Research funding is listed under each investigator the record names.

Medicare prescribing footprint (2023)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Cancer & immunology

    36.8%
    Aromatase Inhibitor15.6%
    Anastrozole74%Letrozole26%
    Part D≥46 patients
    Kinase inhibitor9.7%
    Imbruvica42%Ibrance15%Calquence13%Jakafi13%Imatinib Mesylate9%Cabometyx9%
    Part D<11 patients

    + 4 more classes in this area

  • Nervous system

    21%
    Opioid Agonist6.6%
    Oxycodone Hcl72%Morphine Sulfate Er14%Oxycodone-Acetaminophen14%
    Part D<11 patients
    Benzodiazepine5.9%
    Alprazolam55%Lorazepam30%Diazepam15%
    Part D<11 patients

    + 3 more classes in this area

  • Metabolism & gastrointestinal

    15.4%
    Potassium supplement5.1%
    Potassium Chloride100%
    Part D≥18 patients
    Serotonin-3 Receptor Antagonist5%
    Ondansetron Hcl76%Ondansetron Odt24%
    Part D<11 patients

    + 4 more classes in this area

Where care is delivered (Part B)3.1% facility · 96.9% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet. Reviewed account links and congress post links can appear separately. Absence of a section means “not yet looked,” never “none found.”